LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Topical Nanotechnology Simplifies Skin Disease Diagnosis

By LabMedica International staff writers
Posted on 30 May 2018
Image: A diagram of simplifying disease diagnosis using topically applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed (Photo courtesy of Nanyang Technological University).
Image: A diagram of simplifying disease diagnosis using topically applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed (Photo courtesy of Nanyang Technological University).
Tissue biopsies are necessary for the accurate diagnosis of skin diseases, but their application is limited by the pain, inconvenience, and morbidity experienced by patients, as well as risks of scarring and infection.

Many skin diseases, such as abnormal scars, are typically identified by visual identification of scar lesions; however, a visible scar is already mature, having generated significant newly formed tissue, and is unable to benefit from timely administration of prophylactics.

Scientists at the Nanyang Technological University (Singapore) used NanoFlare to enable biopsy-free disease diagnosis and progression monitoring in response to therapy. It is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks; improve accessibility to disease diagnosis; provide timely feedback of treatment efficacy; and reduce healthcare personnel time and attention, hence the overall healthcare burden.

NanoFlares are inactive and emission signal remains low. NanoFlares targeting reference genes (i.e., Glyceraldehyde-3-Phosphate Dehydrogenase (GapDH) and noncoding sequences) can be simultaneously employed for signal normalization. Thus, abnormal fibroblasts can be discriminated from non-diseased ones by their fluorescence signal. In this process, NanoFlares maintain their detection properties and molecular specificity following transepidermal and intracellular entry.

Transdermal NanoFlare penetration is the results from their unique nanostructure. They comprise highly packed oligonucleotide strands directionally aligned to cores (comprising a range of different materials, including gold) and even hollow-core nanoparticles. This gives the resultant particles a strong negative surface charge.

NanoFlares are topically applied on the lesion, which penetrate the skin barrier, interacting with intracellular mRNA biomarkers. In the presence of the target gene (e.g., disease biomarker or other control genes), mRNA interacts with the NanoFlare, dislodging (releasing) the reporter flare. Leaving the proximity of the gold nanoparticle core, a strong fluorescence is generated. Without target gene hybridization, fluorescence signal does not appreciably increase but remains below background levels. In the presence of sufficient disease biomarker, fluorescence signal can be superficially acquired.

The authors concluded that NanoFlare technology is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks; improve accessibility to disease diagnosis; provide timely feedback of treatment efficacy; and reduce healthcare personnel time and attention, hence the overall healthcare burden. This vision of simplifying disease diagnosis using topically applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed. The study was published on April 13, 2018, in the journal Nature Biomedical Engineering.

Related Links:
Nanyang Technological University

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Automatic CLIA Analyzer
Shine i9000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more